Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer agreed to acquire Anacor for roughly $5.2bn, with the expectation that its late-stage PDE4 inhibitor crisaborole, under review by FDA for the treatment of atopic dermatitis, will generate peak sales of more than $2bn.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q2 2016
Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
Deal Watch: Anacor Purchase Marks Pfizer's Post-Allergan Bolt-On Strategy
Allergan's Fishing For Deals, But Don't Expect A Big Catch

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel